EMD SERONO RESEARCH & DEVELOPMENT INSTITUTE, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Phase 2

Active, not recruiting

Conditions: Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification
Lung Adenocarcinoma Stage IIIB/IV

Interventions: Drug: Tepotinib

First Posted Date: 2016-08-12

Last Posted Date: 2024-08-30

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 337

Registration Number: NCT02864992

Locations: 🇺🇸
Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States
🇺🇸
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸
Wenatchee Valley Hospital & Clinics - ATTN: Jay Johnson, Wenatchee, Washington, United States

and more 154 locations

Efficacy and Safety of Atacicept in IgA Nephropathy

Phase 2

Terminated

Conditions: IgA Nephropathy

Interventions: Drug: Atacicept 75 mg
Drug: Placebo
Drug: Atacicept 25 mg

First Posted Date: 2016-06-21

Last Posted Date: 2021-02-25

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 16

Registration Number: NCT02808429

Locations: 🇺🇸
Ohio State University Clinical Trials Management Office - Ohio State CTMO Parent, Columbus, Ohio, United States
🇺🇸
Southeastern Clinical Research Institute, LLC, Augusta, Georgia, United States
🇺🇸
California Institute of Renal Research - Chula Vista Location, Chula Vista, California, United States

and more 15 locations

Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: M2951
Drug: Placebo

First Posted Date: 2016-05-26

Last Posted Date: 2018-07-17

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 65

Registration Number: NCT02784106

Locations: 🇩🇪
Merck KGaA Communication Center, Darmstadt, Germany
🇺🇸
U.S. Medical Information, Billerica, Massachusetts, United States

Abituzumab in SSc-ILD

Phase 2

Terminated

Conditions: Systemic Sclerosis-associated Interstitial Lung Disease

Interventions: Drug: Abituzumab 1500 mg
Drug: Abituzumab 500 mg
Drug: Placebo

First Posted Date: 2016-04-20

Last Posted Date: 2019-06-18

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 24

Registration Number: NCT02745145

Locations: 🇵🇱
Research site 2, Warszawa, Poland
🇵🇱
Research site 1, Warszawa, Poland
🇬🇧
Research site, Sheffield, West Midlands, United Kingdom

and more 1 locations

First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: VX-984 120 mg + PLD 40 mg/m^2
Drug: VX-984 240 mg + PLD 40 mg/m^2
Drug: VX-984 480 mg + PLD 40 mg/m^2
Drug: VX-984 720 mg + PLD 40 mg/m^2

First Posted Date: 2015-12-31

Last Posted Date: 2019-09-09

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 15

Registration Number: NCT02644278

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Phase 3

Completed

Conditions: Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

Interventions: Drug: Oxaliplatin
Drug: Avelumab
Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: Capecitabine
Other: Best supportive care

First Posted Date: 2015-12-09

Last Posted Date: 2022-06-09

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 499

Registration Number: NCT02625610

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States
🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇫🇷
Centre Georges François Leclerc, Dijon cedex, Côte-d'Or, France

and more 196 locations

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Phase 3

Completed

Conditions: Gastric Cancer Third Line
Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Irinotecan
Drug: Avelumab
Other: Best Supportive Care (BSC)
Drug: Paclitaxel

First Posted Date: 2015-12-09

Last Posted Date: 2020-11-24

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 371

Registration Number: NCT02625623

Locations: 🇺🇸
Advanced Medical Specialties 8940 North Kendall Drive, Suite 300E, Miami, Florida, United States
🇺🇸
New York Oncology Hematology, P.C. 400 Patroon Creek Blvd, Suite 1, Albany, New York, United States
🇺🇸
Oncology Specialists, S.C. 1700 Luther Ln, Ste 2200, Park Ridge, IL 60068 7900 Milwaukee Ave, Ste 16, Niles, Illinois, United States

and more 72 locations

Avelumab in First-line NSCLC (JAVELIN Lung 100)

Phase 3

Completed

Conditions: First Line Non-Small Cell Lung Cancer

Interventions: Drug: Avelumab
Drug: Cisplatin
Drug: Pemetrexed
Drug: Paclitaxel
Drug: Avelumab Weekly
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2015-10-15

Last Posted Date: 2024-03-20

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 1214

Registration Number: NCT02576574

Locations: 🇧🇪
A.Z. Klina, Brasschaat, Belgium
🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇺🇸
Arizona Center for Cancer Care, Surprise, Arizona, United States

and more 344 locations

MSC2364447C Phase 1b in Systemic Lupus Erythematosus

Phase 1

Completed

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: MSC2364447C
Drug: Placebo

First Posted Date: 2015-09-01

Last Posted Date: 2017-10-09

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 24

Registration Number: NCT02537028

Locations: 🇧🇬
Research site, Sofia, Bulgaria

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: MSB0011359C

First Posted Date: 2015-08-07

Last Posted Date: 2024-05-03

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 600

Registration Number: NCT02517398

Locations: 🇺🇸
Pacific Oncology Associates, Escondido, California, United States
🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸
Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States

and more 115 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy